TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Impedimed Limited ( (AU:IPD) ) has issued an update.
ImpediMed Limited announced the CEO’s presentation for the 2025 Annual General Meeting, highlighting the company’s commitment to advancing healthcare standards through its proprietary technology. This announcement underscores ImpediMed’s strategic focus on enhancing its market position by setting new benchmarks in patient care, potentially impacting stakeholders by reinforcing the company’s leadership in medical technology innovation.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing innovative medical devices and services. The company is known for its bioimpedance spectroscopy technology, which is used to assess and monitor fluid status and tissue composition, primarily targeting the healthcare sector.
Average Trading Volume: 1,744,826
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$79.46M
Learn more about IPD stock on TipRanks’ Stock Analysis page.